Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$26.1MCash on Hand
13mo Cash Runway
2.2%Short Interest
$8.41Analyst Target (5)
Follow CRDL by emailGet an email when CRDL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CRDL, unsubscribe in one click. Privacy
📣 What CRDL Says Is Next
mid-2027 · CardiolRx: “Topline results are now anticipated in mid-2027, compared with our previous Q1 2027 guidance.”
Company press release, Sep 23, 2026 · SEC filing
mid-2027 · “Topline results anticipated in mid-2027 following expanded enrollment and study completion.”
Company press release, Sep 23, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 3, 2026 ·
Financing Cardiol Therapeutics entered an at-the-market equity program with Jefferies LLC to sell up to US$75 million of common shares on the Nasdaq Capital Market at prevailing market prices. Form 6-K · SEC filing · Press release
Nov 3, 2026 ·
Financing Cardiol Therapeutics filed an open market sale agreement with Jefferies LLC for up to US$75,000,000 of common shares, sold at the market through Nasdaq with a 3.0% selling commission and a minimum floor price of at least US$1.00. Form 6-K · SEC filing · Press release
Sep 23, 2026 ·
Clinical trial Cardiol reached its 110-patient enrollment target for the Phase III MAVERIC trial of CardiolRx in recurrent pericarditis, ahead of schedule. The steering committee recommends expanding enrollment to up to 150 patients, and topline results are now expected mid-2027 instead of Q1 2027. Cash runway extends into Q1 2028. Form 6-K · SEC filing · Press release
Sep 16, 2026 ·
Financing Cardiol received over USD $7 million from warrant exercises, extending its cash runway into H1 2028. It also gave notice that unexercised warrants (425,000, worth USD $573,750 at the exercise price) will expire October 16, 2026. Form 6-K · SEC filing · Press release
Sep 15, 2026 ·
Cardiol Therapeutics filed its Code of Business Conduct and Ethics as Exhibit 99.1, setting out rules on conflicts of interest, use of corporate assets, inventions, e-mail use, and disclosure, with employees required to sign an annual declaration of compliance. Form 6-K · SEC filing · Press release
Sep 11, 2026 ·
Deal Cardiol filed a Master Services Agreement with Dalton Pharma Services, effective June 12, 2017, under which Dalton is the exclusive contract services provider in the Field. Cardiol will issue shares to Dalton as consideration for the exclusivity, per Appendix B. Form 6-K · SEC filing · Press release
Sep 10, 2026 ·
Financing Cardiol Therapeutics filed a preliminary base shelf prospectus for up to US$150 million in securities, with no offering made yet. The filing also adds expense detail at the request of Ontario regulators, with no restatement of prior financials. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
Cardiol Therapeutics will take part in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT, with a live webcast available on its website. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2026 · Phase 3 · Recruiting · CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not CRDL's own candidates): Cannabidiol.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CRDL holds $26.1M in cash and short-term investments and burns about $6M/quarter from operations,
an estimated runway of 13 months at that rate (BioRadar estimate, not company guidance).
Share count 100,257,009 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CRDL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRDL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.